Dantron
Star0
Identification
- Summary
Dantron is a drug used to relieve acute and chronic inflammation of the oral cavity and oropharynx.
- Generic Name
- Dantron
- DrugBank Accession Number
- DB04816
- Background
Withdrawn from the Canadian, US, and UK markets in 1998 due to genotoxicity.
- Type
- Small Molecule
- Groups
- Approved, Investigational, Withdrawn
- Structure
- Weight
- Average: 240.2109
Monoisotopic: 240.042258744 - Chemical Formula
- C14H8O4
- Synonyms
- 1,8-dihydroxy-9,10-anthracenedione
- 1,8-dihydroxy-9,10-anthraquinone
- 1,8-dihydroxyanthra-9,10-quinone
- 1,8-Dihydroxyanthrachinon
- 1,8-Dihydroxyanthraquinone
- Chrysazin
- Danthron
- Dantron
- Dantrona
- Dantrone
- Dantronum
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
- Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcetazolamide The risk or severity of dehydration can be increased when Acetazolamide is combined with Dantron. Aclidinium The therapeutic efficacy of Dantron can be decreased when used in combination with Aclidinium. Alfentanil The therapeutic efficacy of Dantron can be decreased when used in combination with Alfentanil. Alloin The risk or severity of adverse effects can be increased when Dantron is combined with Alloin. Amantadine The therapeutic efficacy of Dantron can be decreased when used in combination with Amantadine. Amiloride The risk or severity of dehydration can be increased when Amiloride is combined with Dantron. Amiodarone The therapeutic efficacy of Dantron can be decreased when used in combination with Amiodarone. Amitriptyline The therapeutic efficacy of Dantron can be decreased when used in combination with Amitriptyline. Amlodipine The therapeutic efficacy of Dantron can be decreased when used in combination with Amlodipine. Amobarbital The therapeutic efficacy of Dantron can be decreased when used in combination with Amobarbital. Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- No interactions found.
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- International/Other Brands
- Altan / Antrapurol / Bancon / Duolax / Prugol / Roydan / Scatron D / Zwitsalax
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Doss Tab Dantron (50 mg / tab) + Docusate sodium (60 mg / tab) Tablet Oral Smithkline Beecham Pharma Division Of Smithkline Beecham Inc 1993-12-31 1997-12-17 Canada PYRALVEX SOLUCION ORAL Dantron (5 g) + Salicylic acid (1 g) Solution Buccal; Oral 2007-08-08 Not applicable Colombia Regulex D Cap Dantron (50 mg / cap) + Docusate sodium (60 mg / cap) Capsule Oral Whitehall Robins Inc. 1993-12-31 1998-07-29 Canada
Categories
- ATC Codes
- A06AB53 — Dantron, combinations
- A06AB — Contact laxatives
- A06A — DRUGS FOR CONSTIPATION
- A06 — DRUGS FOR CONSTIPATION
- A — ALIMENTARY TRACT AND METABOLISM
- A06AB — Contact laxatives
- A06A — DRUGS FOR CONSTIPATION
- A06 — DRUGS FOR CONSTIPATION
- A — ALIMENTARY TRACT AND METABOLISM
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as anthraquinones. These are organic compounds containing either anthracene-9,10-quinone, 1,4-anthraquinone, or 1,2-anthraquinone.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Anthracenes
- Sub Class
- Anthraquinones
- Direct Parent
- Anthraquinones
- Alternative Parents
- Aryl ketones / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Vinylogous acids / Organic oxides / Hydrocarbon derivatives
- Substituents
- 1-hydroxy-2-unsubstituted benzenoid / 1-hydroxy-4-unsubstituted benzenoid / 9,10-anthraquinone / Anthraquinone / Aromatic homopolycyclic compound / Aryl ketone / Hydrocarbon derivative / Ketone / Organic oxide / Organic oxygen compound
- Molecular Framework
- Aromatic homopolycyclic compounds
- External Descriptors
- dihydroxyanthraquinone (CHEBI:3682) / Anthraquinone type (C10312)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Z4XE6IBF3V
- CAS number
- 117-10-2
- InChI Key
- QBPFLULOKWLNNW-UHFFFAOYSA-N
- InChI
- InChI=1S/C14H8O4/c15-9-5-1-3-7-11(9)14(18)12-8(13(7)17)4-2-6-10(12)16/h1-6,15-16H
- IUPAC Name
- 1,8-dihydroxy-9,10-dihydroanthracene-9,10-dione
- SMILES
- OC1=CC=CC2=C1C(=O)C1=C(C=CC=C1O)C2=O
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0029752
- KEGG Drug
- D07107
- KEGG Compound
- C10312
- PubChem Compound
- 2950
- PubChem Substance
- 46509077
- ChemSpider
- 2845
- BindingDB
- 11316
- 22293
- ChEBI
- 3682
- ChEMBL
- CHEMBL53418
- ZINC
- ZINC000003860369
- PharmGKB
- PA449206
- PDBe Ligand
- CHZ
- Wikipedia
- Dantron
- PDB Entries
- 3nsq
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet Oral Tablet, coated Oral Solution Buccal; Oral Capsule Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 193 °C PhysProp - Predicted Properties
Property Value Source Water Solubility 0.305 mg/mL ALOGPS logP 2.98 ALOGPS logP 3.61 Chemaxon logS -2.9 ALOGPS pKa (Strongest Acidic) 7.89 Chemaxon pKa (Strongest Basic) -5.6 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 74.6 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 65.11 m3·mol-1 Chemaxon Polarizability 23.19 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9899 Blood Brain Barrier + 0.7514 Caco-2 permeable + 0.6963 P-glycoprotein substrate Non-substrate 0.5556 P-glycoprotein inhibitor I Non-inhibitor 0.9605 P-glycoprotein inhibitor II Non-inhibitor 0.9419 Renal organic cation transporter Non-inhibitor 0.8913 CYP450 2C9 substrate Non-substrate 0.7982 CYP450 2D6 substrate Non-substrate 0.9168 CYP450 3A4 substrate Non-substrate 0.7151 CYP450 1A2 substrate Inhibitor 0.8918 CYP450 2C9 inhibitor Inhibitor 0.775 CYP450 2D6 inhibitor Non-inhibitor 0.7456 CYP450 2C19 inhibitor Non-inhibitor 0.6159 CYP450 3A4 inhibitor Non-inhibitor 0.8357 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.7605 Ames test AMES toxic 0.9261 Carcinogenicity Non-carcinogens 0.893 Biodegradation Not ready biodegradable 0.7278 Rat acute toxicity 2.8601 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9505 hERG inhibition (predictor II) Non-inhibitor 0.9192
Spectra
- Mass Spec (NIST)
- Download (8.11 KB)
- Spectra
Carriers
1. DetailsSerum albumin
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Toxic substance binding
- Specific Function
- Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
- Gene Name
- ALB
- Uniprot ID
- P02768
- Uniprot Name
- Serum albumin
- Molecular Weight
- 69365.94 Da
References
- Skupinska K, Zylm M, Misiewicz I, Kasprzycka-Guttman T: Interaction of anthracene and its oxidative derivatives with human serum albumin. Acta Biochim Pol. 2006;53(1):101-12. Epub 2006 Jan 9. [Article]
Drug created at September 11, 2007 20:07 / Updated at June 12, 2021 10:53